贵州百灵企业集团制药股份有限公司 关于2026年第一次临时股东会决议的公告

Core Viewpoint - The company held its first extraordinary general meeting of shareholders in 2026, where no proposals were rejected, and the meeting adhered to legal and regulatory requirements [1][2][3] Meeting Details - The meeting took place on February 13, 2026, with both on-site and online voting options available [2][3] - A total of 621 shareholders attended, representing 270,926,194 shares, which is 19.3851% of the total voting shares [4] - The meeting was chaired by the company's chairman, Jiang Wei, and was legally witnessed by lawyers from Guizhou Beidouxing Law Firm [3][10] Voting Results - Proposal 1, concerning the company's guarantee for a loan application by its subsidiary, was approved with 264,003,921 votes in favor, accounting for 97.4450% of the valid votes [11][12] - Among minority shareholders, 18,158,737 votes were in favor, representing 72.4003% of their valid votes [13] Legal Opinions - The lawyers confirmed that the meeting's procedures and voting were in compliance with relevant laws and regulations, deeming the results valid [14] Risk Warning and Progress Update - The company is under risk warning due to previous disclosures of false information in annual reports from 2019 to 2021 and 2023, as indicated by the administrative penalty notice received from the Guizhou Securities Regulatory Bureau [17][18] - The company is actively addressing the issues raised, including conducting further audits and enhancing internal control measures [18]